dual chimeric antigen receptor cytokine-induced killer cells (IL-3z mutant)

Dual chimeric antigen receptor cytokine-induced killer cells (IL-3z mutant) is an experimental adoptive cellular immunotherapy consisting of cytokine-induced killer (CIK) cells engineered to express two distinct chimeric antigen receptors (CARs). This dual-targeting approach is designed to simultaneously target CD19 and CD123 (interleukin-3 receptor alpha), antigens frequently expressed in hematological malignancies. The CD123-specific CAR component utilizes a mutated version of the human interleukin-3 (IL-3) cytokine as the extracellular targeting domain, which is fused to the CD3-zeta signaling chain (hence "IL-3z mutant"). The mutation in the IL-3 ligand is intended to optimize binding affinity and selectivity for CD123-positive leukemic blasts while potentially minimizing off-target effects on healthy hematopoietic stem cells that also express CD123. CIK cells are a heterogeneous population of effector T cells (CD3+CD56+) generated by the ex vivo expansion of peripheral blood mononuclear cells with IFN-gamma, anti-CD3 antibody, and IL-2, possessing both T-cell and natural killer (NK)-like functional properties. This therapy is primarily investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) to prevent antigen escape and improve therapeutic durability.

Other names

dual-specific CAR-CIK cells targeting CD19 and CD123CD19-CD123 dual CAR-CIK cellsCD-19-CD123 dual CAR-CIK cellsCD 19-CD123 dual CAR-CIK cellsIL-3z mutant dual CAR-CIKIL3z mutant dual CAR-CIKIL 3z mutant dual CAR-CIK